Atopic DermatitisNCT06362629
AI App for Management of Atopic Dermatitis
A study testing Artificial Intelligence assistant decision-making system (AIADMS) App in people with Atopic Dermatitis and Artificial Intelligence, run by West China Hospital at 1 site in China.
Trial summary
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurrent rashes and itching, which seriously affects the quality of life of patients and brings heavy economic burden to society. Read more about this study
- Who is it for?
- Ages 1 year to 75 years
- Conditions the study is for
- Atopic Dermatitis, Artificial Intelligence
- What is being tested?
- Artificial Intelligence assistant decision-making system (AIADMS) App
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 232 participants
- Where
- 1 siteChina
- Study dates
- 1 Sep 2024to 31 Aug 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 75 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Diagnosed with AD, aged 1~75 years; be able to communicate in Chinese; with basic reading and writing skills; participants or the guardian have smartphones or pads and are familiar with the use skills.
Who cannot join
- Mental illness; personality disorder; language barrier; hearing impairment; communication difficulties; with serious coexisting diseases, such as cardiopulmonary insufficiency, liver dysfunction, renal dysfunction, blood system diseases, tumors, or other diseases; other situations that not suitable for participating in clinical trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041
Ren Liao, M.D., +86-18980602177, liaoren7733@163.com
Ren Liao, M.D.
About this study
Official title: Construction and Evaluation of an Artificial Intelligence Assistant Decision-making System Focused on the Treat to Target Framework and Full Process Management for Atopic Dermatitis
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurrent rashes and itching, which seriously affects the quality of life of patients and brings heavy economic burden to society. The Treat to Target (T2T) strategy was proposed to guide optimal use of systemic therapies in patients with moderate to severe AD, and it is emphasized patients' adherence and combined evaluation from both health providers and patients. While effective treatments for AD are available, non-adherence of treatment is common in clinical practice due to the patients' unawareness of self-evaluation and lack of concern about the specific follow-up time points in clinics, which leads to the treatment failure and repeated relapse of AD.
Hypothesis: An Artificial Intelligence assistant decision-making system (AIADMS) with implementation of the T2T framework could help control the disease progression and improve the clinical outcomes for AD.
Read more
Overall objectives:
the investigators aim to develop an AIADMS in the form of smartphone app to integrate T2T approach for both clinicians and patients, and design clinical trials to verify the effectiveness and safety of the app. Methods: This project consists of three parts, AI training model for diagnosis and severity grading of AD based on deep learning, development of Artificial Intelligence assistant decision-making system (AIADMS) in the form of app, and design of a randomized controlled trial to verify the effectiveness and safety of AIADMS App for improvement of the clinical outcomes in AD patients.
Expected results: With application of AIADMS based app, the goal of T2T for patients with AD could be realized better, the prognosis could be improved, and more satisfaction could be achieved for both patients and clinicians.
Impact: This is the first AIADMS based app for AD management running through thediagnosis, patients' self-participation, medical follow-up, and evaluation of achievement of goal of T2T.
Read the detailed description
The project will be executed at the Department of Dermatovenereology, West China Hospital of Sichuan University. The protocol will be approved by the Biological- Medical Ethical Committee of the West China Hospital of Sichuan University, and written informed consent will be obtained from all participants before the investigators take images of the skin lesions and before we recruit them in clinical trials.
- Automatic detection and evaluation of AD based on AI deep learning 1.1 Dataset of atopic dermatitis The dataset will be established from more than 10,000 clinical images of AD patients for AI deep learning. Low-quality images will be excluded, and the images contained the surrounding background will be cropped to include only the AD lesions. 1.2 Labelling the clinical signs of skin lesions The labelling will be completed by three certified dermatologists and three trained algorithm engineers. The dermatologists will label the clinical signs including erythema, papulation, edema, oozing, excoriation, lichenification, and dryness, and severity of each sign will be evaluated and labelled on a four-point scale (0: none, 1: mild, 2: moderate, and 3: severe). The result of each clinical sign in an image will be labelled as an example of erythema-2, edema- 2, or oozing-3. After labelling the images, the dermatologists and algorithm engineers verify the quality of the labelled images from both clinical and labelling rules and cross-validate the accuracy of signs and severity. Images that meet the requirements will be used for model training. During the labelling and model training process, the relevant personnel will be unaware of all the private patient information. 1.3 Model training The model training will be carried out after labelling of the images. An accurate and efficient semantic segmentation model will be trained to distinguish abnormal skin lesion areas to identify all the clinical signs. A fast and accurate pixel level skin segmentation model will be trained to determine the ratio of the lesion area to the overall skin area. Besides, an efficient and practical method to convert the segmented skin lesion area into real skin area units will be created to achieve the accurate restoration of the true size as much as possible from the distortion of the skin lesion because of the shooting distance, angle, or automatic enhancement. The dataset will be divided for training, validation, and testing. Images of 6,500 of 10,000 will be used in training and validation of the proposed model, and images of the remaining 3,500 of 10,000 will be used for testing. After training, combined with the different questionnaire items filled by patients, the evaluative tools including EASI, SCORED, POEM, pp-NRS, and DLQI will be calculated by the model.
- Development of the AIADMS app The app will support the Android system and IOS system, and it will be designed as two versions for both patients and clinicians with the distinguished login entrance. The fundamental function of the app will include "Push", "Reminder", "Upload", "Evaluation", and "Data management". 2.1 The "Push" function is designed to transmit information to patients and medical staff. The pushed information could be received and displayed on the screen of the mobile phone even if the app is not opened and the mobile phone is in the locked screen state, and the users can set the time of receiving the pushed information by themselves. For example, the predetermined time point for follow-up in clinics will be presented as "You should come to see the doctor on next Monday, July 25, 2023". The "Push" function can activate the use of app, increase the viscosity of users, and drive the utilization of other functional modules. 2.2 The "Reminder" function is mainly used for reminding the patients of taking medicine, uploading photos of skin lesions, self-evaluation, and scheduled follow-up. 2.3 The "Upload" function is designed to help patients participate in the systemic treatment. They can upload their photos of skin lesions, the description of progresses of AD, or questionnaires. 2.4 The "Evaluation" function is developed to provide information for both patients and medical staff. By uploading photos of skin lesions and filling in the different questionnaire items, the app will automatically evaluate the severity of lesions and calculate the EASI, POEM, PP-NRS, SCORAD, or DLQI scores. This function could help patients know more about their situation of the disease, and take part in self- evaluation and self-care as the T2T strategy recommended. 2.4 The "Data management" function is designed for medical staff to manage the patients more conveniently and design the medical research. They can log in to the app platform website to collect and export data, carry out statistical analysis and big data mining. App itself can also make simple statistics and management of data. For example, data such as EASI, POEM and PP-NRS score at the time points of before treatment, 2 weeks, 4 weeks, 12 weeks and 6 months after treatment could be automatically generated into statistical reports to presented in the form of histograms or curves. App can also be further improved and updated to the new version through the analysis of users' habits, and the function modules could be optimized with the high frequency of use and the feedback from both medical staff and patients.
- Effectiveness and safety of AIADMS App for improvement of the clinical outcomes in AD patients: a randomized controlled trial.
This trial is a single centered, prospective, randomized controlled trial that test the superiority of the implementation of T2T strategy by application of AIADMS app in patients with AD in term of improvement of clinical outcomes.
This would the first AI assisted tool for AD during the process of diagnosis, management, and follow-up. It will provide solid evidence for the application of AI in dermatology worldwidely.
- Conditions
- Atopic Dermatitis, Artificial Intelligence
- Being tested
- Artificial Intelligence assistant decision-making system (AIADMS) App
- Keywords
- Atopic dermatitis, Treat to Target (T2T) strategy, Artificial Intelligence, app
- Medical subject headings
- Dermatitis, Atopic, Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Artificial Intelligence assistant decision-making system (AIADMS) AppBehavioural
Participants will be assisted to use the Artificial Intelligence assistant decision-making system (AIADMS) app during the process of management of AD, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up.
| Study group | Role | What they receive |
|---|---|---|
| App group | Experimental | Participants will be assisted to use the app during the process of management, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up. Receives: Behavioral: Artificial Intelligence assistant decision-making system (AIADMS) App |
| Control group | No intervention | The diagnosis, treatment, and follow-up of participants will be carried out according to the current routine on face-to-face basis. The time points of the participants follow-up will be determined by the responsible dermatologist, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI will be done and recorded on the day of follow-up. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The overall efficiency rate of treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI at 12 weeks after treatment
The overall efficiency is calculated as "Total number of participants with effective treatment of 5 treating objectives / total number of participants *100%". Criteria for effective treatment are as below: ① PP-NRS absolutely score ≤4, ② EASI -50, EASI -75, or EASI≤7, ③ SCORAD-50, SCORAD-75, or SCORAD ≤24, ④ POEM absolutely score ≤7, ⑤ DLQI absolutely score ≤5.
Measured: 12 months
Secondary outcomes (3)
The seperated efficiency rate of treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI
The seperated efficiency rate of treating objectives is calculated as "Total number of participants with effective treatment of 5 treating objectives / total number of participants *100%".
Measured: 12 months
The economic consumption
The economic consumption will include the travel expenses, expenses with lost working days, accommodation expenses, medical expenses, etc
Measured: 12 months
Satisfaction evaluation
On completion of the study, participants in the App group of the study and healthcare providers will complete respective questionnaires about their use of and satisfaction with the app. Analysis of the satisfaction will be performed collection of the questionnaires.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Apr 2024
- Study start1 Sep 2024
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Aug 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atopic DermatitisStudies of the same condition, open and under way.
- More trials run by West China HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 232 participants (estimated)
Sponsor and investigators
- Lead sponsor
- West China Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ren Liao, Sichuan University
- Investigators
- Jingyi Li, M.D., Principal investigator, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06362629
- Sponsor's protocol ID
- WCH240407
- Status last verified
- Apr 2024
- First submitted
- 8 Apr 2024
- Last updated
- 15 Oct 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Currently, the datasets are not readily available. Individual participant data with anonymity will be uploaded to the IPD sharing platform to achieve data sharing and will be available after the principle investigator's agreement on reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Construction and Evaluation of an Artificial Intelligence Assistant Decision-making System Focused on the Treat to Target Framework and Full Process Management for Atopic Dermatitis
- ClinicalTrials.gov ID
- NCT06362629
- Acronym / sponsor ID
- WCH240407
- Conditions
- Atopic Dermatitis, Artificial Intelligence
- Keywords
- Atopic dermatitis, Treat to Target (T2T) strategy, Artificial Intelligence, app
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 232 participants (estimated)
- Lead sponsor
- West China HospitalUniversity, hospital or other
- Study start
- 1 Sep 2024 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Aug 2029 (estimated)
- First posted
- 12 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurrent rashes and itching, which seriously affects the quality of life of patients and brings heavy economic burden to society. The Treat to Target (T2T) strategy was proposed to guide optimal use of systemic therapies in patients with moderate to severe AD, and it is emphasized patients' adherence and combined evaluation from both health providers and patients. While effective treatments for AD are available, non-adherence of treatment is common in clinical practice due to the patients' unawareness of self-evaluation and lack of concern about the specific follow-up time points in clinics, which leads to the treatment failure and repeated relapse of AD.
Hypothesis: An Artificial Intelligence assistant decision-making system (AIADMS) with implementation of the T2T framework could help control the disease progression and improve the clinical outcomes for AD.
Overall objectives:
the investigators aim to develop an AIADMS in the form of smartphone app to integrate T2T approach for both clinicians and patients, and design clinical trials to verify the effectiveness and safety of the app. Methods: This project consists of three parts, AI training model for diagnosis and severity grading of AD based on deep learning, development of Artificial Intelligence assistant decision-making system (AIADMS) in the form of app, and design of a randomized controlled trial to verify the effectiveness and safety of AIADMS App for improvement of the clinical outcomes in AD patients.
Expected results: With application of AIADMS based app, the goal of T2T for patients with AD could be realized better, the prognosis could be improved, and more satisfaction could be achieved for both patients and clinicians.
Impact: This is the first AIADMS based app for AD management running through thediagnosis, patients' self-participation, medical follow-up, and evaluation of achievement of goal of T2T.
Detailed description
The project will be executed at the Department of Dermatovenereology, West China Hospital of Sichuan University. The protocol will be approved by the Biological- Medical Ethical Committee of the West China Hospital of Sichuan University, and written informed consent will be obtained from all participants before the investigators take images of the skin lesions and before we recruit them in clinical trials.
- Automatic detection and evaluation of AD based on AI deep learning 1.1 Dataset of atopic dermatitis The dataset will be established from more than 10,000 clinical images of AD patients for AI deep learning. Low-quality images will be excluded, and the images contained the surrounding background will be cropped to include only the AD lesions. 1.2 Labelling the clinical signs of skin lesions The labelling will be completed by three certified dermatologists and three trained algorithm engineers. The dermatologists will label the clinical signs including erythema, papulation, edema, oozing, excoriation, lichenification, and dryness, and severity of each sign will be evaluated and labelled on a four-point scale (0: none, 1: mild, 2: moderate, and 3: severe). The result of each clinical sign in an image will be labelled as an example of erythema-2, edema- 2, or oozing-3. After labelling the images, the dermatologists and algorithm engineers verify the quality of the labelled images from both clinical and labelling rules and cross-validate the accuracy of signs and severity. Images that meet the requirements will be used for model training. During the labelling and model training process, the relevant personnel will be unaware of all the private patient information. 1.3 Model training The model training will be carried out after labelling of the images. An accurate and efficient semantic segmentation model will be trained to distinguish abnormal skin lesion areas to identify all the clinical signs. A fast and accurate pixel level skin segmentation model will be trained to determine the ratio of the lesion area to the overall skin area. Besides, an efficient and practical method to convert the segmented skin lesion area into real skin area units will be created to achieve the accurate restoration of the true size as much as possible from the distortion of the skin lesion because of the shooting distance, angle, or automatic enhancement. The dataset will be divided for training, validation, and testing. Images of 6,500 of 10,000 will be used in training and validation of the proposed model, and images of the remaining 3,500 of 10,000 will be used for testing. After training, combined with the different questionnaire items filled by patients, the evaluative tools including EASI, SCORED, POEM, pp-NRS, and DLQI will be calculated by the model.
- Development of the AIADMS app The app will support the Android system and IOS system, and it will be designed as two versions for both patients and clinicians with the distinguished login entrance. The fundamental function of the app will include "Push", "Reminder", "Upload", "Evaluation", and "Data management". 2.1 The "Push" function is designed to transmit information to patients and medical staff. The pushed information could be received and displayed on the screen of the mobile phone even if the app is not opened and the mobile phone is in the locked screen state, and the users can set the time of receiving the pushed information by themselves. For example, the predetermined time point for follow-up in clinics will be presented as "You should come to see the doctor on next Monday, July 25, 2023". The "Push" function can activate the use of app, increase the viscosity of users, and drive the utilization of other functional modules. 2.2 The "Reminder" function is mainly used for reminding the patients of taking medicine, uploading photos of skin lesions, self-evaluation, and scheduled follow-up. 2.3 The "Upload" function is designed to help patients participate in the systemic treatment. They can upload their photos of skin lesions, the description of progresses of AD, or questionnaires. 2.4 The "Evaluation" function is developed to provide information for both patients and medical staff. By uploading photos of skin lesions and filling in the different questionnaire items, the app will automatically evaluate the severity of lesions and calculate the EASI, POEM, PP-NRS, SCORAD, or DLQI scores. This function could help patients know more about their situation of the disease, and take part in self- evaluation and self-care as the T2T strategy recommended. 2.4 The "Data management" function is designed for medical staff to manage the patients more conveniently and design the medical research. They can log in to the app platform website to collect and export data, carry out statistical analysis and big data mining. App itself can also make simple statistics and management of data. For example, data such as EASI, POEM and PP-NRS score at the time points of before treatment, 2 weeks, 4 weeks, 12 weeks and 6 months after treatment could be automatically generated into statistical reports to presented in the form of histograms or curves. App can also be further improved and updated to the new version through the analysis of users' habits, and the function modules could be optimized with the high frequency of use and the feedback from both medical staff and patients.
- Effectiveness and safety of AIADMS App for improvement of the clinical outcomes in AD patients: a randomized controlled trial.
This trial is a single centered, prospective, randomized controlled trial that test the superiority of the implementation of T2T strategy by application of AIADMS app in patients with AD in term of improvement of clinical outcomes.
This would the first AI assisted tool for AD during the process of diagnosis, management, and follow-up. It will provide solid evidence for the application of AI in dermatology worldwidely.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| App group | Experimental | Behavioral: Artificial Intelligence assistant decision-making system (AIADMS) AppParticipants will be assisted to use the app during the process of management, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up. |
| Control group | No intervention | –The diagnosis, treatment, and follow-up of participants will be carried out according to the current routine on face-to-face basis. The time points of the participants follow-up will be determined by the responsible dermatologist, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI will be done and recorded on the day of follow-up. |
Who may qualify
- Ages
- 1 year to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Diagnosed with AD, aged 1~75 years; be able to communicate in Chinese; with basic reading and writing skills; participants or the guardian have smartphones or pads and are familiar with the use skills.
Key exclusion criteria (1 listed)
- Mental illness; personality disorder; language barrier; hearing impairment; communication difficulties; with serious coexisting diseases, such as cardiopulmonary insufficiency, liver dysfunction, renal dysfunction, blood system diseases, tumors, or other diseases; other situations that not suitable for participating in clinical trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Artificial Intelligence assistant decision-making system (AIADMS) AppParticipants will be assisted to use the Artificial Intelligence assistant decision-making system (AIADMS) app during the process of management of AD, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up. | Behavioural | App group |
Primary outcome
The overall efficiency rate of treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI at 12 weeks after treatment
Time frame: 12 months
The overall efficiency is calculated as "Total number of participants with effective treatment of 5 treating objectives / total number of participants *100%". Criteria for effective treatment are as below: ① PP-NRS absolutely score ≤4, ② EASI -50, EASI -75, or EASI≤7, ③ SCORAD-50, SCORAD-75, or SCORAD ≤24, ④ POEM absolutely score ≤7, ⑤ DLQI absolutely score ≤5.
3 secondary outcomes
The seperated efficiency rate of treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI
Time frame: 12 months
The economic consumption
Time frame: 12 months
Satisfaction evaluation
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2024.
- Individual participant dataSharing planned: Yes. Currently, the datasets are not readily available. Individual participant data with anonymity will be uploaded to the IPD sharing platform to achieve data sharing and will be available after the principle investigator's agreement on reasonable request.
Related trials for Atopic Dermatitis
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jingyi Li, M.D. principal investigator
West China Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Artificial Intelligence assistant decision-making system (AIADMS) App in people with Atopic Dermatitis and Artificial Intelligence, run by West China Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jingyi Li, M.D. (+8618980605704, jingyili@wchscu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The overall efficiency rate of treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI at 12 weeks after treatment (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2024.